Plain-English translation of NCT04010877 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1/2 — A combined trial that checks safety and dosing while also starting to look at whether the treatment works.
This trial is testing a new approach to treating acute myeloid leukemia (AML), a fast-growing blood cancer. Doctors will take your immune cells, genetically modify them in the laboratory to recognize and attack leukemia cells, and then give them back to you through an infusion. The treatment uses multiple types of engineered cells to target different markers on leukemia cells and prevent the cancer from coming back.
Current AML treatments don't always work long-term because cancer cells can escape or hide from the immune system. This trial is designed to test whether targeting multiple features of leukemia cells at once will be more effective and reduce the risk of relapse.
You likely qualify if…
You likely don't qualify if…
If you enroll, doctors will collect your immune cells and send them to a laboratory to be genetically modified over several weeks. Once the engineered cells are ready, you will receive them back as an intravenous infusion. You will then be monitored closely to see how well the treatment works, whether you experience any side effects, and how long the modified cells stay active in your body.
AI-generated summary from trial data · Jun 26, 2026 · Not medical advice
China
Phase
Safety & dosing / Early efficacy
Sponsor
Shenzhen Geno-Immune Medical Institute
Enrollment target
~10 participants
Started
August 2025
Primary completion
July 2028
Age range
6 Months – 75 Years
Last updated on clinicaltrials.gov in June 2026.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Lung-Ji Chang, Ph.D
Shenzhen Geno-Immune Medical Institute
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.